The 3 Questions Every CEO Should Be Asking Their Biotech IP Team Today

1. What is our current IP position, and do we know the score?

Your IP score reflects how defensible, differentiated, and commercially aligned your patent

portfolio is today. It is the clearest snapshot of whether your innovations are protectable, whether

competitors can design around them, and whether investors will view your IP as a true asset

rather than a placeholder.

A CEO cannot chart a credible development or fundraising path without knowing where the

company stands right now.

Ask your team:

•  Do we have a current, objective assessment of our IP strength?
•  Are we confident in what is actually protectable versus what is aspirational?
•  Are we guessing, or do we have a structured evaluation framework?

LifeSci-IP provides a rapid, founder friendly IP Position Audit to establish your baseline and

identify gaps before they become costly.

2. Do we have a written strategy that aligns IP protection with our commercial objectives?

Strong IP does not happen by accident. High value portfolios are built through deliberate, staged

decisions that map scientific innovation to commercial reality.

Your patents must protect not only what you invented, but what you intend to sell, license, or

partner around. Without a written strategy, teams default to reactive filing, which leads to weak

claims, misaligned filings, and lost exclusivity.

Ask your team:

•  Do we have a documented IP strategy tied to our product roadmap?
•  Are we protecting the right inventions, not just the most recent ones?
•  Do our claims support future revenue, partnerships, and regulatory milestones?
•  Are we proactively shaping the narrative investors and acquirers will, see?

LifeSci-IP specializes in building IP strategies that position your company as the premier choice

in your therapeutic or technology space.

3. Do we have a system in place to track IP progress and portfolio maturity?

IP development is not a onetime project; it is an ongoing discipline. As your science evolves,

your IP must evolve with it. As competitors publish, your strategy must adapt. As your

commercial plan shifts, your claims must be refined.

Tracking IP maturity monthly (at minimum) ensures your company stays ahead of competitive

threats and continues to build enterprise value.

Ask your team:

•  Are we monitoring competitor filings and publications?
•  Do we have a cadence for reviewing claim scope, new data, and new inventions?
•  Are we measuring whether our IP is becoming more defensible over time?
•  Do we have a dashboard or system to track progress?

LifeSci-IP provides structured IP tracking systems that ensure your portfolio grows in strength,

clarity, and commercial relevance.

THE BOTTOM LINE: TWO THINGS EVERY BIOTECH EXECUTIVE MUST UNDERSTAND

1. If your IP cannot secure exclusivity, you will not secure investment, partnerships, or

market share. As the attached document notes: “You can't chart a path forward until you know

where you stand today.”

2. IP strategy is a specialized discipline, not an extension of R&D or legal operations. Just as

the attached briefing states that optimization requires new skills, IP strategy requires expertise

beyond basic patent drafting. Most early stage teams need fractional, specialized support to avoid

avoidable missteps.

LifeSci-IP partners with founders and scientific teams to build IP portfolios that protect

innovation, accelerate partnerships, and materially increase valuation.